Advertisement
Advertisement
U.S. Markets open in 1 hr 30 mins
Advertisement
Advertisement
Advertisement
Advertisement

Veru Inc. (VERU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.76+0.19 (+3.41%)
At close: 04:00PM EST
5.70 -0.06 (-1.02%)
Pre-Market: 08:00AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.57
Open5.51
Bid0.00 x 1200
Ask5.75 x 1300
Day's Range5.51 - 5.99
52 Week Range4.34 - 24.55
Volume2,124,928
Avg. Volume4,273,321
Market Cap460.971M
Beta (5Y Monthly)-0.20
PE Ratio (TTM)250.43
EPS (TTM)0.02
Earnings DateFeb 07, 2023 - Feb 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 28, 2014
1y Target Est36.25
  • GlobeNewswire

    Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023

    MIAMI, FL, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Thursday, February 9, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 first quarter financial results and provide a business update. The audio webcast will be accessible under “Investor Kit” in the Investors page of the Compa

  • Simply Wall St.

    Those who invested in Veru (NASDAQ:VERU) five years ago are up 364%

    Some Veru Inc. ( NASDAQ:VERU ) shareholders are probably rather concerned to see the share price fall 44% over the last...

  • GlobeNewswire

    Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

    MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). “Today’s appointment of Dr. Ho as Chairman of Veru’s SAB illustrates our commitment to building a team of sc

Advertisement
Advertisement